GET DAILY SIGNALSFractyl Health (GUTS) Shares Drop -81% Amid Questions Over Revita Data
Key Takeaways
- Fractyl Health (GUTS) shares fell roughly 81% over the last 30 days, sliding from about $5.83 to near $1.13, even after the company reported "positive" six-month pivotal data for its Revita device.
- The decline accelerated on October 16, 2026, when the stock dropped more than 50% in a single session as investors questioned the size and durability of the treatment benefit.
- A securities class-action lawsuit, analyst downgrades, and steep price-target cuts compounded the selling pressure and weighed on confidence in the company's disclosures.
- The stock is down roughly 86% over the last quarter, extending a multi-month slide that began with a disappointing interim readout in January 2026.
- A pending 12-month co-primary endpoint (expected in Q1 2027) and a planned De Novo FDA submission in late Q4 2026 are the key clinical and regulatory catalysts ahead.
Fractyl Health (GUTS) Company Background
Fractyl Health, Inc. (Nasdaq: GUTS) is a clinical-stage metabolic therapeutics company based in Burlington, Massachusetts. The company is developing therapies intended to treat the root causes of obesity and type 2 diabetes rather than simply managing symptoms. Its lead candidate, the Revita DMR System, is an outpatient endoscopic procedure that resurfaces the duodenal lining and is being studied for weight maintenance in people who discontinue GLP-1 therapy. The company has also advanced Rejuva, a gene therapy platform targeting pancreatic islet cells. Investors follow GUTS because it sits at the intersection of two high-growth markets — GLP-1 weight-loss drugs and metabolic disease — and because its pipeline carries a binary, event-driven risk profile typical of pre-revenue biotechnology companies.
Fractyl Health (GUTS) Recent Stock Performance
Over the last 30 days, GUTS shares fell approximately 81%, from a closing price of about $5.83 on September 23, 2026, to roughly $1.13 in late October. The bulk of the loss occurred in a single session on October 16, when the stock dropped more than 50% despite the company announcing that its REMAIN-1 Pivotal Cohort had met a six-month co-primary endpoint.
The move was even steeper when viewed over the full quarter. From a level near $8.28 in late July 2026, the stock declined roughly 86%, reflecting a sustained de-rating rather than an isolated one-day shock. The broader trend has been one of persistent selling pressure, punctuated by sharp, high-volume down days tied to clinical data releases and legal developments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Drivers Behind the Last 30 Days of Trading
The dominant catalyst was the October 16, 2026 release of top-line six-month results from the REMAIN-1 Pivotal Cohort, a 308-participant, sham-controlled study of Revita for post-GLP-1 weight maintenance. Revita-treated patients retained about 80% of their GLP-1-driven weight loss versus 67% in the sham arm, with a least-squares mean weight regain of 5.1% compared with 8.2% (p=0.0023). Although the endpoint was met, the effect size was viewed as modest and broadly consistent with a January interim readout that had already disappointed investors, and the pivotal trial's second co-primary endpoint — 12-month maintenance of at least 5% weight loss — remains unread.
The selloff was amplified by a securities class-action lawsuit alleging that the company made misleading statements about Revita's effectiveness and clinical prospects. Morgan Stanley downgraded the stock to Equal-weight and cut its price target, while other analysts trimmed their targets. The pressure continued into late October, when Fractyl announced a workforce reduction of about 45%, the discontinuation of internal development of its Rejuva program, and leadership changes, further signaling a strategic reset focused solely on Revita.
Performance Over the Past Quarter and Underlying Factors
The quarterly decline reflects a longer-running loss of investor confidence. In late January 2026, six-month data from the REMAIN-1 Midpoint Cohort showed Revita patients regained 4.5% of their weight versus 7.5% in the control group — a result that fell short of expectations and triggered a one-day drop of roughly 68%. That episode damaged the company's credibility, and the subsequent class-action litigation has kept a cloud over the shares.
Beyond the clinical story, Fractyl's balance sheet has shaped sentiment. As a pre-revenue company with cash expected to fund operations only into early 2027 and management citing "substantial doubt" about its ability to continue as a going concern, investors have priced in the risk of future dilution and the uncertainty of a regulatory path that could stretch into 2028.
Key Events to Watch Going Forward
The most consequential near-term event for GUTS is the 12-month data from the REMAIN-1 Pivotal Cohort, expected in the first quarter of 2027, which will read out the second co-primary endpoint. Ahead of that, investors will watch whether the company files its planned De Novo marketing application with the FDA in late Q4 2026 and how regulators respond. A Category III CPT code is scheduled to take effect on January 1, 2027, which could support future reimbursement. On the financial side, cash runway, the potential for additional capital raises, and the outcome of the securities litigation will remain key risks, as will the company's ability to execute a leaner, Revita-focused strategy following its workforce reduction.
Exploring AI Tools for Market Analysis
In my own work, I regularly look at Tickeron’s Trending AI Robots to see how automated strategies are responding to names facing sharp volatility. The page curates top-performing bots from a large universe, each with different approaches and timeframes, helping identify systematic ways to navigate current conditions without any guarantees on results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
GUTS's RSI Oscillator stays in oversold zone for 14 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 104 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GUTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GUTS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GUTS's P/B Ratio (-108.032) is very low in comparison to the industry average of (2.973). P/E Ratio (-1.242) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (438.009).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. GUTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement